Platinum-based chemotherapy in early-stage triple negative breast cancer: A meta-analysis

Triple negative breast cancer (TNBC), accounts for approximately 15% of early-stage breast cancer diagnoses and is characterized by a younger age at diagnosis and more aggressive features such as more advanced stage and worse survival [1,2]. TNBC is a heterogeneous disease, which can include chemoresistant cases which are associated with early relapse and adverse outcomes and a contrasting group of chemosensitive tumors which with multimodality therapy can have a very low risk of relapse [3]. Pre-clinical data suggest that TNBC are associated with dysfunctional DNA-repair mechanisms (e.g.

Source: Cancer Treatment Reviews - August 28, 2021 Category: Cancer & Oncology Authors: Ramy R. Saleh, Michelle B. Nadler, Alexandra Desnoyers, Nicholas Meti, Rouhi Fazelzad, Eitan Amir Source Type: research